CID s.r.l., a European company leader in interventional medicine, will update interventional cardiologists on the status of their revolutionary drug eluting stent technology during The Drug Eluting Stent (DES) Summit at TCT 2010, Washington, DC on Wednesday, September 22, 2010. The lecture, entitled "Status of the CID Cre8 polymer-free DES program", will be delivered by Alexandre Abizaid, MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo Brazil, and will be part of the session "The Next Generation DES, Polymer-Free".

Some of the highlights of the presentation will include an exploration of the clinical benefits of CID's Abluminal Reservoir Technology (ART) and drug delivery technology. By surrounding molecules of drug with amphiphilic carriers and embedding them into reservoirs on the stent's outer surface, CID drug-eluting stents are able to deliver drug to the coronary arteries without using any polymers, which can cause serious complications in patients.

CID's unique ART system with its amphiphilic carrier is more physiological and patients who receive these stents are less likely to have inflammation and thrombosis within their coronary arteries. Moreover CID DES technology features an integral Bio-Inducer Surface (BIS) which implies less medication to prevent blood clotting after the stent has been deployed for enhanced safety.

Commenting on the innovative technology in its new Cre8 DES, Franco Vallana, Chief Executive Officer of CID s.r.l. said, "We have always known that the more the stent and the drug delivery system are designed and developed to harmonize with the human body, the better the short- and long-term results will be. Combining ART with our innovative drug formulation with amphiphilic carrier into a completely polymer-free stent will allow doctors to provide their patients with stents that are more physiological and complement the body's natural systems."

Source: CID s.r.l.